Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
REDWOOD CITY, Calif., May 30, 2017 -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that management will present at two upcoming investment conferences:
- 14th Annual Craig-Hallum Institutional 1x1 Investor Conference on Wednesday, May 31st at The Depot Renaissance Minneapolis Hotel in Minneapolis.
- Jefferies 2017 Global Healthcare Conference on Thursday, June 8, at 2:30 p.m. Eastern time (11:30 a.m. Pacific time). The conference will be held in New York City.
A live webcast and replay of the presentation at the Jefferies Global Healthcare Conference will be available on the Investors section of the company’s website, http://ir.codexis.com/.
About Codexis, Inc.
Codexis, Inc. is a leading protein engineering company that applies its technology to the development of biocatalysts for commercial manufacture of pharmaceuticals and fine chemicals, as well as the development of enzymes as biotherapeutics and for molecular diagnostics. Codexis’ proven technology enables implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable manufacturing. For more information, see www.codexis.com.
Contacts: Investors LHA Jody Cain, 310 691 7100 [email protected]
